NCT07862582Not yet recruitingPhase 1/2
RYZ711 Diagnostic Platform Study
Phase 1 /2 Multicenter, Basket, Imaging Study Investigating the Safety and Diagnostic Performance of RYZ711 in Men With Prostate Cancer.
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed adenocarcinoma of the prostate.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- First submitted
- 1 Oct 2026
- Start date
- Oct 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- RayzeBio, Inc.
- Diseases
- Prostate cancer
- NCT number
- NCT07862582
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 116
- From Oct 2026 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cohort 1: Any prior prostate cancer therapy
- Cohort 2: Ongoing or recent ADT (within 3 months prior to Day 1)
- Cohort 3: Prior ¹⁷⁷Lu-PSMA therapy within 6 weeks of PSMA PET/CT
Other illness
- Neuroendocrine, sarcomatoid, or spindle cell prostate cancer
- Non-prostate metastatic malignancy
Lab values
- eGFR \< 60 mL/min, QTcF \> 470 ms, impaired hepatic function
Other
- Subjects who meet any of the following criteria will be excluded from the study:
Who the study is looking for
- Subjects who meet all of the following criteria are eligible for inclusion in the study:
- Histologically confirmed adenocarcinoma of the prostate
- ECOG PS ≤ 2
- Planned or scheduled PSMA PET/CT scan
- Cohort 1: Unfavorable intermediate-risk or higher per NCCN 2026 guidelines, with planned RP and extended PLND within 6 weeks of RYZ711 PET/CT
- Cohort 2: Rising PSA after definitive therapy meeting standard BCR criteria (AUA 2026 or Phoenix criteria)
- Cohort 3: mHSPC or mCRPC with documented disease progression; candidate for PSMA-targeted radiopharmaceutical therapy
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Omaha | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.